​

Neurogene Stock (NASDAQ:NGNE)

ForecastRevenueOwnershipFinancialsChart
Neurogene by TradingView

Previous Close

$9.03

52W Range

$6.88 - $74.49

50D Avg

$15.66

200D Avg

$30.56

Market Cap

$133.92M

Avg Vol (3M)

$272.92K

Beta

1.47

Div Yield

-

NGNE Company Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

107

IPO Date

Mar 07, 2014

Website

NGNE Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 24
Reportable Segment$925.00K

Fiscal year ends in Dec 24 | Currency in USD

NGNE Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-82.61M$-55.58M$-56.52M
Net Income$-75.14M$-36.32M$-55.19M
EBITDA$-82.61M$-52.29M$-51.99M
Basic EPS-$-2.83$-4.30
Diluted EPS-$-2.83$-4.30

Fiscal year ends in Dec 24 | Currency in USD